CN103946218B - 抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用 - Google Patents

抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用 Download PDF

Info

Publication number
CN103946218B
CN103946218B CN201280036645.XA CN201280036645A CN103946218B CN 103946218 B CN103946218 B CN 103946218B CN 201280036645 A CN201280036645 A CN 201280036645A CN 103946218 B CN103946218 B CN 103946218B
Authority
CN
China
Prior art keywords
crystal form
compound
mixed solvent
preparation
tetrahydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280036645.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103946218A (zh
Inventor
康心汕
龙伟
王飞
马存波
周刘峰
胡云雁
王燕萍
曹红
王印祥
谭芬来
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING BETA PHARMA Inc
Original Assignee
BEIJING BETA PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING BETA PHARMA Inc filed Critical BEIJING BETA PHARMA Inc
Priority to CN201280036645.XA priority Critical patent/CN103946218B/zh
Publication of CN103946218A publication Critical patent/CN103946218A/zh
Application granted granted Critical
Publication of CN103946218B publication Critical patent/CN103946218B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN201280036645.XA 2011-07-29 2012-07-30 抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用 Expired - Fee Related CN103946218B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280036645.XA CN103946218B (zh) 2011-07-29 2012-07-30 抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN2011102158266 2011-07-29
CN201110215826.6 2011-07-29
CN201110215826 2011-07-29
CN2011102196075 2011-08-02
CN201110219607 2011-08-02
CN201110219607.5 2011-08-02
CN201110232754 2011-08-15
CN201110232754.6 2011-08-15
CN2011102327546 2011-08-15
CN201280036645.XA CN103946218B (zh) 2011-07-29 2012-07-30 抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用
PCT/CN2012/079361 WO2013017063A1 (en) 2011-07-29 2012-07-30 Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof

Publications (2)

Publication Number Publication Date
CN103946218A CN103946218A (zh) 2014-07-23
CN103946218B true CN103946218B (zh) 2016-03-09

Family

ID=47628644

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036645.XA Expired - Fee Related CN103946218B (zh) 2011-07-29 2012-07-30 抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用

Country Status (10)

Country Link
US (1) US9238637B2 (https=)
EP (1) EP2736892A4 (https=)
JP (1) JP2014523917A (https=)
KR (1) KR20140076549A (https=)
CN (1) CN103946218B (https=)
AU (1) AU2012289563A1 (https=)
CA (1) CA2843240A1 (https=)
IL (1) IL230682A0 (https=)
WO (1) WO2013017063A1 (https=)
ZA (1) ZA201401448B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6506390B2 (ja) 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． キノリノン系化合物及びその薬物への使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505725A (zh) * 2006-08-29 2009-08-12 特瓦制药工业有限公司 包含含维生素D的化合物和皮质类固醇化合物的具有低pH相容性的稳定的药理学活性组合物
WO2011006355A1 (en) * 2009-07-15 2011-01-20 Beijing Beta Pharma Inc. Compounds as hypoxia mimetics, and compositions, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324405B2 (en) * 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505725A (zh) * 2006-08-29 2009-08-12 特瓦制药工业有限公司 包含含维生素D的化合物和皮质类固醇化合物的具有低pH相容性的稳定的药理学活性组合物
WO2011006355A1 (en) * 2009-07-15 2011-01-20 Beijing Beta Pharma Inc. Compounds as hypoxia mimetics, and compositions, and uses thereof

Also Published As

Publication number Publication date
US20140343137A1 (en) 2014-11-20
AU2012289563A1 (en) 2014-03-13
KR20140076549A (ko) 2014-06-20
EP2736892A1 (en) 2014-06-04
IL230682A0 (en) 2014-03-31
US9238637B2 (en) 2016-01-19
AU2012289563A2 (en) 2014-07-03
EP2736892A4 (en) 2015-03-18
WO2013017063A1 (en) 2013-02-07
ZA201401448B (en) 2015-04-29
CN103946218A (zh) 2014-07-23
JP2014523917A (ja) 2014-09-18
CA2843240A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
CN104024227B (zh) 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
TW200404060A (en) Fused heterocyclic compounds
JP2025038060A (ja) ピリミジンホルムアミド化合物及びその使用
JP5972986B2 (ja) Ｃｄｄｏエチルエステルの多形体及びその用途
JP2014534208A5 (https=)
CN103946218B (zh) 抑制脯氨酸羟化酶活性的化合物的稳定晶型及其应用
JP2019527708A (ja) Ｄｐｐ−ｉｖ長時間作用型阻害剤の結晶及びその塩
JPS6219583A (ja) ピリドンカルボン酸誘導体、そのエステルおよびその塩
TWI582078B (zh) 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
CN119371391B (zh) 一种芳甲酰类化合物及其制备方法与用途
TWI811901B (zh) 一種嘧啶甲醯胺類化合物及其應用
TW201321361A (zh) 抑制脯氨酸羥化酶活性的化合物的穩定晶型及其應用
CN118026948A (zh) 三联芳环类化合物及其制备方法、药物组合物和应用
CN120774808A (zh) 一类苄基苯胺衍生物及其用途
HK40077414A (en) Pyrimidine formamide compound and use thereof
JPH0348674A (ja) 新規なクマリン誘導体，その製法及び用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160309